Cannabidiphorol (CBDP) acts as a negative allosteric modulator at two distinct sites of cannabinoid receptor 1

Abstract While Δ9-tetrahydrocannabinol (THC) offers significant pain relief, its psychoactive side effects limit its clinical utility. The discovery of cannabidiol (CBD) as a negative allosteric modulator (NAM) of cannabinoid receptor 1 (CB1R) establishes allosteric targeting as a viable framework for refining cannabinoid-based therapeutics. Cannabidiphorol (CBDP), a naturally occurring homolog of CBD identified from the FM2 chemovar of Cannabis sativa, is structurally similar to CBD but its pharmacology is largely unexplored. This study investigated the potential of CBDP as a NAM